Bingnan Zhang

Oncology

210 Ashville Ave # 408
Cary, NC 27518

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 37 publications

Real-World Experience of Tarlatamab in Extensive-Stage Small Cell Lung Carcinoma Showed Promising Systemic and Intracranial Efficacy With Higher Neurologic Toxicity.

Real-World Experience of Tarlatamab in Extensive-Stage Small Cell Lung Carcinoma Showed Promising Systemic and Intracranial Efficacy With Higher Neurologic Toxicity.

Journal: JCO precision oncology

Published: April 23, 2026

First Report of Response to Tarlatamab in a Patient With Histologic-Transformed SCLC From ALK-Rearranged NSCLC: Case Report.

First Report of Response to Tarlatamab in a Patient With Histologic-Transformed SCLC From ALK-Rearranged NSCLC: Case Report.

Journal: JTO clinical and research reports

Published: January 26, 2026

CyTOF-based profiling of circulating tumor cells predicts aggressiveness and therapy response in SCLC liquid biopsies at a personalized level.

CyTOF-based profiling of circulating tumor cells predicts aggressiveness and therapy response in SCLC liquid biopsies at a personalized level.

Journal: bioRxiv : the preprint server for biology

Published: December 25, 2025

YAP1 defines an emergent, plastic population of relapsed small cell lung cancer.

YAP1 defines an emergent, plastic population of relapsed small cell lung cancer.

Journal: bioRxiv : the preprint server for biology

Published: November 24, 2025

The Impact of Targeting TRAF2 and NCK-Interacting Protein Kinase on Antitumor Effect and Tumor Immune Environment in c-MYC-High SCLC.

The Impact of Targeting TRAF2 and NCK-Interacting Protein Kinase on Antitumor Effect and Tumor Immune Environment in c-MYC-High SCLC.

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Published: November 21, 2025

A multi-institutional perspective on tarlatamab administration and management of CRS/ICANS.

A multi-institutional perspective on tarlatamab administration and management of CRS/ICANS.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: November 17, 2025

Tarlatamab population survival kinetics in extensive-stage small cell lung cancer: brief report.

Tarlatamab population survival kinetics in extensive-stage small cell lung cancer: brief report.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: November 09, 2025

Multi-Institution Analysis of Tarlatamab for the Treatment of EGFR-Mutant Transformed Small Cell Lung Cancer.

Multi-Institution Analysis of Tarlatamab for the Treatment of EGFR-Mutant Transformed Small Cell Lung Cancer.

Journal: JCO precision oncology

Published: October 30, 2025

MET Overexpression Is Associated with Superior Immunotherapy Benefit in Advanced Non-Small Cell Lung Cancer.

MET Overexpression Is Associated with Superior Immunotherapy Benefit in Advanced Non-Small Cell Lung Cancer.

Journal: Cancers

Published: October 24, 2025

YAP1 defines an emergent, plastic population of relapsed small cell lung cancer.

YAP1 defines an emergent, plastic population of relapsed small cell lung cancer.

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Published: October 21, 2025

YAP1 Defines an Emergent, Plastic Population of Relapsed SCLC.

YAP1 Defines an Emergent, Plastic Population of Relapsed SCLC.

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Published: October 21, 2025

Sacituzumab govitecan: another emerging treatment option for patients with relapsed small cell lung cancer.

Sacituzumab govitecan: another emerging treatment option for patients with relapsed small cell lung cancer.

Journal: Translational lung cancer research

Published: May 01, 2025

Showing 1-12 of 37

Last Updated: 09/26/2026